Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Babini, G. S.
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Babini, G. S.
Right arrow Articles by Livermore, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 105-109
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC ß-lactamases

Gioia S. Babini and David M. Livermore*

Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK

Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC enzymes, was tested against ß-lactamase-producing bacteria with piperacillin, piperacillin–tazobactam and ceftazidime as partner drugs. In the presence of conalbumin as an iron chelator, Syn 2190 potentiated these drugs against most AmpC producers, although Klebsiella spp. with plasmidic AmpC enzymes were an exception. Potentiation was much weaker without conalbumin, suggesting that Syn 2190 exploits a ferric uptake pathway, as do catecholic cephalosporins. Syn 2190 had little ability to potentiate partner drugs against strains with other ß-lactamase types but, with conalbumin, increased the activity of piperacillin–tazobactam against Escherichia coli transconjugants producing various class A or D enzymes.

* Corresponding author. Tel: + 44-181-200-4400 ext. 4223; Fax: + 44-181-200-7449; E-mail: DLivermore{at}phls.nhs.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C. E. Jamieson, P. A. Lambert, and I. N. Simpson
In Vitro and In Vivo Activities of AM-112, a Novel Oxapenem
Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1652 - 1657.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Danes, M. M. Navia, J. Ruiz, F. Marco, A. Jurado, M. T. Jimenez de Anta, and J. Vila
Distribution of {beta}-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different {beta}-lactam antibiotics
J. Antimicrob. Chemother., August 1, 2002; 50(2): 261 - 264.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.